FDA Clears Mustang Bio’s IND for MB-102 (CD123-CAR T)

FDA Clears Mustang Bio’s IND for MB-102 (CD123-CAR T)

Mustang Bio, Inc (MBIO) reports that the U.S. Food and Drug Administration (FDA) has approved the Company’s investigational new dug application (IND) in acute myeloid leukemia (AML) blastic plasmacytoid dendritic cell neoplasm (BPDCN) and high-risk myelodysplastic...

Pin It on Pinterest